Two Step Versus the Standard Three Step Approach of the WHO Analgesic Ladder for Cancer Pain Relief.

Overview

The World Health Organization analgesic ladder for cancer pain relief is an internationally used approach to managing cancer pain. Patients generally start on Step 1 of the ladder (paracetamol). As pain increases or is not well controlled on this, they progress to Step 2 which involves a stronger pain killer (weak opioid such as codeine). If pain is still not controlled they progress to Step 3 of the ladder which is a strong opioid (such as morphine). Work to date has suggested that Step 2 may be unnecessary and most patients usually require Step 3 analgesia. The TVT trial aims to examine the standard approach (Step 1-Step2-Step-3) versus a two step approach (Step 1-Step 3).

Full Title of Study: “An International, Multicentre, Open Randomised Parallel Group Trial Comparing a Two Step Approach for Cancer Pain Relief With the Standard Three Step Approach of the WHO Analgesic Ladder in Patients With Cancer Pain Requiring Step 2 Analgesia.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2016

Interventions

  • Other: analgesic ladder
    • Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 – Step 2 – Step 3).
  • Other: analgesic ladder
    • Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.

Arms, Groups and Cohorts

  • Active Comparator: Standard 3 Step approach.
    • Standard 3 Step approach of the WHO analgesic ladder (Step 1 – Step 2 – Step 3).
  • Experimental: 2 Step approach.
    • 2 Step approach of the WHO analgesic ladder (Step 1 – Step 3).

Clinical Trial Outcome Measures

Primary Measures

  • Time to achieving stable pain control, where stable pain control is defined as the first day of three consecutive days with average pain score less than or equal to 3 using scores from the Patient Diary and patient assessments.
    • Time Frame: Up to 20 days

Participating in This Clinical Trial

Inclusion Criteria

  • 18 years of age and over. – Patient has a cancer diagnosis (based on radiological, histological, cytological, or operative evidence). Those with haematological malignancies are eligible. – Cancer related pain – which in the opinion of the clinician is caused by the presence of tumour or metastases. – Average pain score > 4, on a numerical rating scale from 0-10, requiring step 2 analgesia (weak opioid). – Patient is able to comply with trial procedures. Exclusion Criteria:

  • Patients who have received radiotherapy in the previous 6 weeks or are planned to receive radiotherapy during the trial period where in either case, it is expected to affect pain during the trial period. – Pain due to surgery in the preceding 4 weeks. – Life expectancy less than two months (based on clinical impression). – Patients with psychotic disorders or cognitive impairment. – Patients who have received regular doses (scheduled doses – NOT as required dosing) of weak or strong opioids in the preceding two weeks. – Patients using immediate release opioids > 2 doses/24 hours, in the previous 24 hours.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Edinburgh
  • Collaborator
    • NHS Lothian
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marie Fallon, Principal Investigator, University of Edinburgh

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.